Clinical Commander

Back to dossier
cardio.acute-hf.constrictive-pericarditis-decompensation.v1PRODUCTION
cardio.acute-hf.constrictive-pericarditis-decompensation.v1

Acute HF — constrictive pericarditis decompensation

cardiologyacuteadult
Hard-required inputs
0 / 7
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Constrictive pericarditis decompensation: rigid pericardium → impaired diastolic filling → R-sided > L-sided HF + low CO; etiology drives surgical risk (radiation worst); definitive therapy is pericardiectomy; gentle diuresis acutely; differentiate from RCM

Inputs
1
Actions
0
Advance rule
Set
Advance when

CP framed

Patient inputs (11)

Elevated ESR/CRP + LGE on MRI suggests active inflammation potentially responsive to anti-inflammatory therapy (NSAID + colchicine ± steroid) per ESC 2015 — may avoid surgery in subset

Older patients more likely to have post-cardiac-surgery or post-radiation CP; younger patients more likely TB or post-viral; age also drives surgical risk for pericardiectomy

Etiology drives prognosis (radiation CP has worst surgical outcomes), reversibility (active inflammation may respond to anti-inflammatory therapy avoiding surgery), and adjunct therapy (ATT for TB, steroids for CTD)

eGFR drives diuretic dosing; chronic R-sided HF causes hepatic congestion + cardiac cirrhosis (elevated bilirubin, AST/ALT, INR — pseudo-hepatorenal physiology)

Septal bounce, expiratory hepatic vein reversal, respirophasic interventricular septal shift, annulus reversus (medial e prime > lateral e prime — preserved or elevated), preserved LV systolic function, biatrial enlargement — distinguishes from restrictive cardiomyopathy

JVP elevation + Kussmaul sign + pulsus paradoxus (less prominent than tamponade) + low SBP often + narrow pulse pressure — clinical exam essential

BNP often disproportionately LOW in CP relative to symptoms (myocardium not stretched due to constraint) — markedly elevated BNP favors RCM; useful differential clue

Pericardial thickening >4 mm + late gadolinium enhancement (active inflammation = potentially reversible) + tagged imaging showing pericardial-myocardial adhesion — gold standard noninvasive

Pericardial calcification (~25% of CP cases — pathognomonic when present) + thickening; alternative to MRI when MRI contraindicated; also evaluates lung pathology for radiation/TB

Definitive hemodynamic confirmation: rapid Y descent in RA, dip-and-plateau (square root) sign in RV/LV diastolic pressures, equalization of RA/RV/PCWP within 5 mmHg, ventricular interdependence with discordant systolic pressures (Hatle sign) — high specificity for CP vs RCM

TB pericarditis common in endemic regions + immunosuppressed; PPD/IGRA, AFB cultures, pericardial fluid (if drainable) for TB PCR + ADA; ATT essential before pericardiectomy (avoid intra-op TB seeding)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningpost_pericardiectomy_low_output_state
    Post-pericardiectomy low-output syndrome (LOS) — LV dysfunction unmasked when constraint removed; CI <2.2 + lactate elevation + oliguria + hypotension despite adequate preload
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningeffusive_constrictive_pericarditis_with_tamponade_physiology
    Pericardial effusion superimposed on constriction — tamponade physiology with elevated RA + JVD + Kussmaul + pulsus paradoxus; pericardiocentesis only partially relieves due to underlying constriction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererefractory_ascites_with_renal_dysfunction_in_constrictive_pericarditis
    Tense ascites unresponsive to diuretic + new renal dysfunction (rising creatinine, oliguria) — cardiac cirrhosis with hepatorenal-like physiology in CP
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepericardiectomy_decision_in_radiation_associated_constrictive_pericarditis
    Radiation-associated CP requiring pericardiectomy — high surgical mortality (~30% per Murashita 2017) due to coexisting myocardial fibrosis, valvular disease, CAD, adhesions, and pulmonary fibrosis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererestrictive_vs_constrictive_differential_unresolved
    Diagnostic uncertainty between RCM and CP after echo + MRI — both have preserved EF + diastolic dysfunction + biatrial enlargement; clinical implications major (CP curable, RCM not)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Constrictive pericarditis acute decompensation — gentle diuresis + treat active inflammation if applicable + pericardiectomy referral (ESC 2015 PMID 26320112; Khandaker Mayo Clin Proc 2010 PMID 20656240; IMPI PMID 25180860 for TB-CP)
axis: constrictive_pericarditis_decompensation_phenotype
Selected axis "Constrictive pericarditis acute decompensation — gentle diuresis + treat active inflammation if applicable + pericardiectomy referral (ESC 2015 PMID 26320112; Khandaker Mayo Clin Proc 2010 PMID 20656240; IMPI PMID 25180860 for TB-CP)" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    10-20 mg IV titrated to UOP + clinical response (NOT high-dose upfront — preload-dependent low-output state) • IV • q12-24h titrate
    triggers: constrictive_pericarditis_with_congestion_or_ascites
    Gentle diuresis essential — over-diuresis precipitates pre-renal AKI in preload-dependent low-output state; titrate to symptom relief without hypotension; daily weight + BMP guides dosing
    rxcui 4603
  • spironolactone
    add on
    mineralocorticoid_receptor_antagonist
    25-50 mg PO daily • PO • daily
    triggers: constrictive_pericarditis_with_ascites_or_hepatic_congestion, avoid_hypokalemia_with_loop_diuretic
    Cardiac cirrhosis physiology — spironolactone first-line for ascites in cirrhosis (cardiac or hepatic); also K-sparing partner with loop diuretic
    rxcui 9997
  • ibuprofen
    first line
    nsaid
    600 mg PO TID × 2-4 wk then taper • PO • TID
    triggers: active_inflammation_high_crp_lge_on_mri, recurrent_pericarditis_with_evolving_constriction
    ESC 2015 PMID 26320112 + Imazio CORP trials — NSAID first-line for active pericarditis; potentially reverses early constriction if active inflammation present (subset of "transient constrictive pericarditis" per Haley Mayo 2004)
    rxcui 5640
  • colchicine
    first line
    microtubule_inhibitor
    0.5 mg PO daily (<70 kg) or 0.5 mg PO BID (≥70 kg) × 3 mo • PO • daily-BID
    triggers: active_pericarditis_with_evolving_constriction, recurrent_pericarditis_prevention
    ESC 2015 + Imazio CORP-2 PMID 24819631 — colchicine reduces recurrence + may prevent progression to chronic CP; renal dose-adjust
    rxcui 2683
  • prednisone
    add on
    corticosteroid_glucocorticoid
    0.25-0.5 mg/kg/d PO (LOW-DOSE per ESC 2015 — high-dose worsens pericarditis recurrence) × weeks then taper • PO • daily
    triggers: ctd_associated_pericarditis_with_constriction, refractory_inflammation_after_nsaid_colchicine_failure, tb_pericarditis_per_impi_subset
    ESC 2015 — low-dose only after NSAID + colchicine failure or in CTD; high-dose paradoxically increases recurrence (Imazio); IMPI PMID 25180860 — adjunct steroid in TB-CP failed primary endpoint but may reduce constriction in HIV-negative subset
    rxcui 8640
  • isoniazid
    comorbidity specific
    antimycobacterial
    5 mg/kg/d PO (max 300 mg) × 2 mo intensive then 4 mo continuation • PO • daily
    triggers: tb_pericarditis_confirmed_or_high_suspicion
    WHO 2022 TB guideline — 4-drug intensive (HRZE) × 2 mo then HR × 4 mo; pyridoxine 25 mg daily for INH neuropathy prevention; pre-pericardiectomy ATT essential to avoid intra-op TB seeding
    rxcui 6038
  • rifampin
    comorbidity specific
    antimycobacterial
    10 mg/kg/d PO (max 600 mg) • PO • daily
    triggers: tb_pericarditis_confirmed_or_high_suspicion
    WHO 2022 — part of HRZE intensive phase; many drug interactions (CYP3A4 inducer)
    rxcui 9384
  • pyrazinamide
    comorbidity specific
    antimycobacterial
    25 mg/kg/d PO (max 2 g) × 2 mo • PO • daily × 2 mo intensive only
    triggers: tb_pericarditis_intensive_phase
    WHO 2022 — intensive phase; hepatotoxicity + hyperuricemia common AEs
    rxcui 8987
  • ethambutol
    comorbidity specific
    antimycobacterial
    15-25 mg/kg/d PO × 2 mo • PO • daily × 2 mo intensive
    triggers: tb_pericarditis_intensive_phase
    WHO 2022 — intensive phase; optic neuritis monitoring; renal dose-adjust
    rxcui 142435
  • metoprolol_succinate
    comorbidity specific
    beta_blocker_b1_selective
    12.5-25 mg PO daily titrate (LOW dose, careful — preload-dependent state) • PO • daily
    triggers: afib_in_constrictive_pericarditis, persistent_tachycardia_above_100
    AFib common in CP via atrial dilation; rate control essential but avoid HR <60 (impairs CO when stroke volume is fixed); BB preferred over CCB for HFrEF if coexisting LV dysfunction
    rxcui 6918
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) • PO • BID
    triggers: afib_in_constrictive_pericarditis_with_chads_vasc_above_2
    ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred; apixaban for elderly per ARISTOTLE PMID 21870978
    rxcui 1364430

outpatient playbook — drug actions (4)

  1. 1. maintenance diuretics for residual congestion
    rxcui 4603
    furosemide PO + spironolactone titrate • PO • daily
    trigger: residual congestion post-pericardiectomy or chronic medical
    Symptom-guided
  2. 2. GDMT if LV dysfunction unmasked post-pericardiectomy
    rxcui 1656328
    sacubitril-valsartan + BB + MRA + SGLT2i per HFrEF protocol • PO • as scheduled
    trigger: unmasked HFrEF post-surgery
    2022 ACC/AHA HF Class I
  3. 3. continue colchicine 3 mo post-acute inflammation
    rxcui 2683
    0.5 mg PO daily-BID • PO • daily-BID
    trigger: active inflammation maintenance
    Imazio
  4. 4. complete ATT 6 mo if TB pericarditis
    rxcui 6135
    HRZE × 2 mo + HR × 4 mo • PO • daily
    trigger: TB pericarditis
    WHO 2022 + IMPI

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Right-sided HF features (JVD, hepatomegaly, ascites, peripheral edema) dominant over pulmonary edema + preserved LV EF on echo → constrictive pericarditis pathway; New right-sided HF in patient with prior CABG/valve/transplant OR mediastinal radiation (breast, lung, lymphoma — often years-decades delayed) — high pretest probability of CP; Echo septal bounce + expiratory hepatic vein flow reversal + preserved LV EF + biatrial enlargement → CP suspicion + advanced imaging (cardiac MRI + cath).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — constrictive pericarditis decompensation** (cardio.acute-hf.constrictive-pericarditis-decompensation.v1).
Scope: Constrictive pericarditis decompensation: rigid pericardium → impaired diastolic filling → R-sided > L-sided HF + low CO; etiology drives surgical risk (radiation worst); definitive therapy is pericardiectomy; gentle diuresis acutely; differentiate from RCM

No severity triggers fired against current inputs.

Plan

Regimen axis: **Constrictive pericarditis acute decompensation — gentle diuresis + treat active inflammation if applicable + pericardiectomy referral (ESC 2015 PMID 26320112; Khandaker Mayo Clin Proc 2010 PMID 20656240; IMPI PMID 25180860 for TB-CP)**.
1. furosemide 10-20 mg IV titrated to UOP + clinical response (NOT high-dose upfront — preload-dependent low-output state) IV q12-24h titrate (loop_diuretic, first line) — Gentle diuresis essential — over-diuresis precipitates pre-renal AKI in preload-dependent low-output state; titrate to symptom relief without hypotension; daily weight + BMP guides dosing
2. spironolactone 25-50 mg PO daily PO daily (mineralocorticoid_receptor_antagonist, add on) — Cardiac cirrhosis physiology — spironolactone first-line for ascites in cirrhosis (cardiac or hepatic); also K-sparing partner with loop diuretic
3. ibuprofen 600 mg PO TID × 2-4 wk then taper PO TID (nsaid, first line) — ESC 2015 PMID 26320112 + Imazio CORP trials — NSAID first-line for active pericarditis; potentially reverses early constriction if active inflammation present (subset of "transient constrictive pericarditis" per Haley Mayo 2004)
4. colchicine 0.5 mg PO daily (<70 kg) or 0.5 mg PO BID (≥70 kg) × 3 mo PO daily-BID (microtubule_inhibitor, first line) — ESC 2015 + Imazio CORP-2 PMID 24819631 — colchicine reduces recurrence + may prevent progression to chronic CP; renal dose-adjust
5. prednisone 0.25-0.5 mg/kg/d PO (LOW-DOSE per ESC 2015 — high-dose worsens pericarditis recurrence) × weeks then taper PO daily (corticosteroid_glucocorticoid, add on) — ESC 2015 — low-dose only after NSAID + colchicine failure or in CTD; high-dose paradoxically increases recurrence (Imazio); IMPI PMID 25180860 — adjunct steroid in TB-CP failed primary endpoint but may reduce constriction in HIV-negative subset
6. isoniazid 5 mg/kg/d PO (max 300 mg) × 2 mo intensive then 4 mo continuation PO daily (antimycobacterial, comorbidity specific) — WHO 2022 TB guideline — 4-drug intensive (HRZE) × 2 mo then HR × 4 mo; pyridoxine 25 mg daily for INH neuropathy prevention; pre-pericardiectomy ATT essential to avoid intra-op TB seeding
7. rifampin 10 mg/kg/d PO (max 600 mg) PO daily (antimycobacterial, comorbidity specific) — WHO 2022 — part of HRZE intensive phase; many drug interactions (CYP3A4 inducer)
8. pyrazinamide 25 mg/kg/d PO (max 2 g) × 2 mo PO daily × 2 mo intensive only (antimycobacterial, comorbidity specific) — WHO 2022 — intensive phase; hepatotoxicity + hyperuricemia common AEs
9. ethambutol 15-25 mg/kg/d PO × 2 mo PO daily × 2 mo intensive (antimycobacterial, comorbidity specific) — WHO 2022 — intensive phase; optic neuritis monitoring; renal dose-adjust
10. metoprolol_succinate 12.5-25 mg PO daily titrate (LOW dose, careful — preload-dependent state) PO daily (beta_blocker_b1_selective, comorbidity specific) — AFib common in CP via atrial dilation; rate control essential but avoid HR <60 (impairs CO when stroke volume is fixed); BB preferred over CCB for HFrEF if coexisting LV dysfunction
11. apixaban 5 mg PO BID (or 2.5 mg BID per dose-reduction criteria) PO BID (doac_factor_xa_direct, comorbidity specific) — ACC/AHA 2023 AFib (PMID 38033089) — DOAC preferred; apixaban for elderly per ARISTOTLE PMID 21870978

Setting playbook (outpatient) — Long-term management — post-pericardiectomy surveillance OR chronic medical for inoperable patients; cardiology + CT surgery + cardiac rehab; complete TB therapy if applicable
12. maintenance diuretics for residual congestion furosemide PO + spironolactone titrate PO daily — residual congestion post-pericardiectomy or chronic medical (Symptom-guided)
13. GDMT if LV dysfunction unmasked post-pericardiectomy sacubitril-valsartan + BB + MRA + SGLT2i per HFrEF protocol PO as scheduled — unmasked HFrEF post-surgery (2022 ACC/AHA HF Class I)
14. continue colchicine 3 mo post-acute inflammation 0.5 mg PO daily-BID PO daily-BID — active inflammation maintenance (Imazio)
15. complete ATT 6 mo if TB pericarditis HRZE × 2 mo + HR × 4 mo PO daily — TB pericarditis (WHO 2022 + IMPI)

Non-pharmacologic actions:
- Cardiac rehab maintenance phase post-pericardiectomy
- CT surgery follow-up at 1-3-6-12 mo
- Annual TB screen if HIV+ or endemic exposure
- Goals of care reassessment for chronic medical management trajectory

AVOID / contraindication checks:
- Avoid_aggressive_diuresis_in_constrictive_pericarditis (preload dependent low output state — over diuresis causes pre renal AKI + hypotension)
- Avoid_pure_arterial_vasodilators (nitroprusside, hydralazine — reduce preload + worsen low output state)
- Avoid_high_dose_steroids_in_idiopathic_pericarditis (ESC 2015 — paradoxically increases recurrence; use ≤0.5 mg/kg/d only after NSAID + colchicine failure or in CTD)
- Steroids_contraindicated_in_tb_pericarditis_without_concurrent_att (worsens TB; IMPI showed adjunct steroid acceptable WITH ATT in HIV negative)
- Rate_control_avoid_hr_below_60 (CP has fixed stroke volume; bradycardia drops CO)
- Colchicine_renal_dose_adjust_avoid_with_strong_cyp3a4_inhibitors (clarithromycin, ketoconazole — fatal toxicity)
- Ibuprofen_avoid_if_egfr_below_30_or_active_gi_bleed
- Rifampin_drug_interactions_review_all_meds (CYP3A4 inducer reduces apixaban, warfarin, statins, etc.)
- Pericardiectomy_high_risk_in_radiation_associated_cp (~30% perioperative mortality per Murashita 2017 — multidisciplinary discussion essential)
- Isoniazid_check_lfts_baseline_and_monthly (hepatotoxicity)
- Ethambutol_baseline_visual_acuity_and_color_vision (optic neuritis)

Monitoring

Regimen monitoring:
- daily weight io strict
- daily bmp for aki with diuresis
- serial jvp exam
- daily lfts inr for cardiac cirrhosis trend
- echo at 4 6 wk post anti inflammatory therapy if active inflammation (assess reversibility before surgery)
- inr q week during warfarin (if used over apixaban for AFib)
- monthly lfts during att phase for inh rfp pza hepatotoxicity
- baseline and monthly visual acuity color vision during ethambutol
- cd4 and hiv status during tb pericarditis management
- post pericardiectomy inotrope milrinone or dobutamine may be needed for low output state

Setting (outpatient) monitoring:
- Quarterly cardiology + echo at intervals
- Annual LFTs if cardiac cirrhosis
- INR + drug levels if warfarin

Follow-up plan: Cardiac surgery referral for pericardiectomy at high-volume center if surgical candidate; cardiology follow-up at 1-2 weeks; nephrology if cardiorenal physiology; hepatology if cardiac cirrhosis; ID + pulmonary if TB; oncology if radiation; post-pericardiectomy follow-up at 1 wk + 1 mo + 3 mo + 6 mo (low-output state in early post-op period requires close monitoring; LV dysfunction may unmask requiring GDMT initiation)
- Close-out criterion: long-term plan documented + surgical referral booked

Monitoring phase: Continuous SpO2 + ECG + BP (hypotension risk with diuresis in preload-dependent state); strict I/O; daily weight + abdominal girth (ascites); daily BMP for AKI + electrolytes; serial JVP exam; INR + LFTs for cardiac cirrhosis trend; echo at 4-6 wk post-anti-inflammatory therapy if active inflammation (assess reversibility before surgery)

Disposition

Current setting: outpatient — Long-term management — post-pericardiectomy surveillance OR chronic medical for inoperable patients; cardiology + CT surgery + cardiac rehab; complete TB therapy if applicable

Disposition criteria:
- Long-term continuation; if pericardiectomy successful + no recurrence at 1 yr → routine cardiology follow-up; if chronic medical → ongoing surveillance with palliative care integration if quality of life poor

Escalation triggers (move to higher acuity):
- Recurrent decompensation → admission
- Late residual constriction → repeat surgical evaluation
- New LV dysfunction post-pericardiectomy → GDMT + cardiology
- TB recurrence → ID + repeat workup

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Post-pericardiectomy low-output syndrome (LOS) — LV dysfunction unmasked when constraint removed; CI <2.2 + lactate elevation + oliguria + hypotension despite adequate preload
- [LIFE_THREATENING] Pericardial effusion superimposed on constriction — tamponade physiology with elevated RA + JVD + Kussmaul + pulsus paradoxus; pericardiocentesis only partially relieves due to underlying constriction
- [SEVERE] Tense ascites unresponsive to diuretic + new renal dysfunction (rising creatinine, oliguria) — cardiac cirrhosis with hepatorenal-like physiology in CP

Citations

- ESC 2015 pericardial diseases (Adler PMID 26320112) + Khandaker Mayo Clin Proc 2010 (PMID 20656240) + Sagristà-Sauleda EHJ 2002 (PMID 12122206) + IMPI for TB pericarditis (PMID 25180860) [PMID:26320112](https://pubmed.ncbi.nlm.nih.gov/26320112/)
- Cited evidence (PMID 20656240) [PMID:20656240](https://pubmed.ncbi.nlm.nih.gov/20656240/)
- Cited evidence (PMID 12122206) [PMID:12122206](https://pubmed.ncbi.nlm.nih.gov/12122206/)
- Cited evidence (PMID 25180860) [PMID:25180860](https://pubmed.ncbi.nlm.nih.gov/25180860/)
- Cited evidence (PMID 24819631) [PMID:24819631](https://pubmed.ncbi.nlm.nih.gov/24819631/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC 2015 pericardial diseases (Adler PMID 26320112) + Khandaker Mayo Clin Proc 2010 (PMID 20656240) + Sagristà-Sauleda EHJ 2002 (PMID 12122206) + IMPI for TB pericarditis (PMID 25180860) — PMID:26320112
  • Cited evidence (PMID 20656240) — PMID:20656240
  • Cited evidence (PMID 12122206) — PMID:12122206
  • Cited evidence (PMID 25180860) — PMID:25180860
  • Cited evidence (PMID 24819631) — PMID:24819631